TargImmune News
March 2019
TargImmune is proud to announce that its project ‘A Next-generation targeted immuno-oncology therapy’ (NEXIM) was awarded a SME Instrument Phase 1 grant of the European Commission. The aim of the NEXIM project was to perform detailed market and competitor analysis and to search for funding opportunities, as to enable TargImmune to make sound positioning and prioritization decisions on its drug assets. Outcomes of the research supported the company in the focusing of its development plans and provided information to refine the company’s business plans.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868342.
March 2019
TargImmune was awarded a Nano Argovia grant together with the Department of Chemistry at the University of Basel, and the Department of Biosystems Science and Engineering at ETH Zurich to characterize a novel, targeted immuno-oncology approach. The groups are studying nanoparticles that smuggle a specific cargo into cancer cells. This cargo concurrently triggers targeted cancer cell killing and an anti-tumor immune response, destroying the tumors. In the Nano Argovia project NCT Nano, the researchers are identifying key parameters that are necessary to support the development of TargImmune’s novel therapeutic, TAR001 for the clinic.
September 2018
TargImmune Therapeutics and a team of researchers from the University Hospital Basel were awarded an Innosuisse grant to generate translational models and delineate the mechanism of action of TargImmune’s lead compound, TAR001. These activities will provide critical data for the clinical development of TAR001.
23 November 2017
Australian researchers have been called in to join an international effort to fight cancer using a new technique that boosts the body’s immune system. Known as immunotherapy, the treatment seeks to target individual cancer cells while also boosting the patient’s immune system so cancerous tissues are destroyed whilst leaving healthy areas untouched. This is in contrast to more usual cancer treatments like radiation or chemotherapy that take a blanket approach, targeting the cancerous cells in a way that also affects normal tissues.
23 November 2017
Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the development of a cutting-edge cancer immunotherapy platform. Building on the expertise of Professor Alexander Levitzki’s 15-year development of this technology, leading Walter and Eliza Hall Institute cancer researcher Professor Tony Burgess will use TargImmune’s novel drug platform for pre-clinical research at WEHI. TargImmune CEO Dr Esteban Pombo-Villar said the company’s proprietary technology…
21 November 2017
Perth researchers have been called in to join an international effort to fight cancer using a new technique that boosts the body’s immune system. Known as immunotherapy, the treatment seeks to target individual cancer cells while also boosting the patient’s immune system so cancerous tissues are destroyed whilst leaving healthy areas untouched. This is in contrast to more usual cancer treatments like radiation or chemotherapy that take a blanket approach, targeting the cancerous cells in a way that also affects normal tissues. The treatment is being advanced by Swiss biotech company TargImmune…
21 November 2017
Australian researchers have been called in to join an international effort to fight cancer using a new technique that boosts the body’s immune system. Known as immunotherapy, the treatment seeks to target individual cancer cells while also boosting the patient’s immune system so cancerous tissues are destroyed whilst leaving healthy areas untouched. This is in contrast to more usual cancer treatments like radiation or chemotherapy that take a blanket approach, targeting the cancerous cells in a way that also affects normal tissues.
21 November 2017
The Melbourne-based Walter and Eliza Hall Institute has signed a new international research collaboration with Swiss biotech company TargImmune focussed on progressing development of a cutting-edge cancer immunotherapy platform. As part of the collaboration, Walter and Eliza Hall Institute cancer researcher Professor Tony Burgess will use TargImmune’s novel drug platform for pre-clinical research at WEHI. TargImmune Therapeutics AG was established in March 2016. According to TargImmune CEO, Dr Esteban Pombo-Villar, the company’s technology platform involves a personalised approach…
11 July 2017
The Basel-based company TargImmune Therapeutics AG and the Australian Race Oncology Limited are entering into a joint venture to develop new cancer therapies. The R&D work will be done in Basel. TargImmune Therapeutics and Race Oncology announced that they have executed a letter of intent to establish a joint venture called Race Immunotherapeutics (RITX). The joint venture, which will be equally co-owned by both parties, will focus on developing new cancer therapies. RITX will develop the new therapies based on a TargImmune technology that was in-licensed from the Hebrew University…
10 July 2017
Australian-based specialist pharmaceutical firm Race Oncology has executed a Letter of Intent (LoI) with Swiss-based biotechnology TargImmune Therapeutics to enter a joint venture (JV) between the two companies to develop new and improved cancer therapies. The new 50:50 JV is to be called Race Immunotherapeutics (RITX) and will focus on developing these therapies based on combining Race’s chemotherapy drug, Bisantrene, with TargImmune’s targeted cancer therapy technology. The new intellectual property created by RITX will be equally co-owned by both parties…
Press Releases
20 November 2017
Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the development of a cutting-edge cancer immunotherapy platform. Building on the expertise of Professor Alexander Levitzki’s 15-year development of this technology, leading Walter and Eliza Hall Institute cancer researcher Professor Tony Burgess will use TargImmune’s novel drug platform for pre-clinical research at WEHI. TargImmune CEO Dr Esteban Pombo-Villar said the company’s proprietary technology…
10 July 2017
Race Oncology Limited (ASX: RAC) announced today that it has executed a Letter of Intent with TargImmune Therapeutics AG (Basel, Switzerland) to enter into a joint venture between the two companies. The joint venture, to be called Race Immunotherapeutics, will focus on developing new and improved cancer therapies based on combining Bisantrene with TargImmune’s targeted cancer therapy technology. The Race Immunotherapeutics (“RITX”) joint venture will be a 50:50 partnership between Race and TargImmune, and all new intellectual property created by RITX…